Analyst Reco. Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
26.55 ^USD	+1.45%		+2.19%	-15.79%

03-27	Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	MT
03-21	Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	03-21	MT
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	03-11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	03-08	MT
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating	02-08	MT
Canaccord Genuity Initiates Arcturus Therapeutics With Buy Rating, $81 Price Target	12-13	MT
William Blair Initiates Arcturus Therapeutics Holdings at Outperform Rating	24/07/23	MT
HC Wainwright Upgrades Arcturus Therapeutics Holdings to Buy From Neutral, Price Target at $51	11/05/23	MT
Goldman Sachs Adjusts Price Target on Arcturus Therapeutics Holdings to $14 From $8, Maintains Sell Rating	10/11/22	MT
Baird Downgrades Arcturus Therapeutics Holdings to Underperform From Neutral, Price Target is $18	10/11/22	MT
Barclays Upgrades Arcturus Therapeutics Holdings to Equalweight From Underweight, Adjusts Price Target to $25 From $16	02/11/22	MT
Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration	02/11/22	DJ
Cantor Fitzgerald Raises Price Target on Arcturus Therapeutics Holdings to $44 From $39, Keeps Overweight Rating	02/11/22	MT
US Futures Nudge Higher Ahead of Federal Reserve Board Meeting; Fourth Straight Rate Hike Expected	02/11/22	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $98 From $105, Reiterates Overweight Rating	10/08/22	MT
Barclays Trims Price Target on Arcturus Therapeutics Holdings to $16 From $17, Reiterates Underweight Rating	10/08/22	MT
Raymond James Downgrades Arcturus Therapeutics Holdings to Underperform From Market Perform	10/08/22	MT
Cantor Fitzgerald Assumes Arcturus Therapeutics Holdings at Overweight, Sets $39 Price Target	19/07/22	MT
Goldman Sachs Adjusts Arcturus Therapeutics Holdings' Price Target to $8 from $14, Keeps Sell Rating	24/05/22	MT
Baird Upgrades Arcturus Therapeutics Holdings to Neutral From Underperform, Cuts Price Target to $18 From $21	11/05/22	MT
Barclays Adjusts Arcturus Therapeutics Holdings' Price Target to $17 from $21, Keeps Underweight Rating	10/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Analyst Reco.

Filters